FAQ

FAQ published on September 18, 2013
Dr. Andrew Zelenetz discusses first-line and second-line therapy for Hodgkin lymphoma patients in relapse.
FAQ published on September 18, 2013
Dr. Andrew Zelenetz discusses the various steps and diagnostic tools used to diagnose, stage and risk-stratify patients.
FAQ published on August 21, 2013
Dr. Tim Illidge discusses if FDG-PET is a viable indicator for radiotherapy in patients with early stage Hodgkin lymphoma.
FAQ published on August 21, 2013
Dr. Tim Illidge discusses the approval of the targeted antibody agent, brentuximab vedotin, and where the agent fits into the current treatment paradigm.
FAQ published on June 14, 2013
Dr. James Armitage discusses risks associated with therapy for Hodgkin lymphoma.
FAQ published on June 14, 2013
Dr. James Armitage discusses the key goals in treating patients with Hodgkin lymphoma.
FAQ published on June 14, 2013
Dr. James Armitage discusses the current standard optimal chemotherapy regimen for patients with Hodgkin lymphoma.
Page 6 of 6
Results 51 - 57 of 57

Managing HL would like to recognize and thank Merck & Co., Inc., Seattle Genetics, and Takeda Oncology for their educational support of ManagingHodgkinLymphoma.com

©2017 MediCom Worldwide, Inc. All rights reserved